2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
17
Prostatic Neoplasms
6
Ovarian Neoplasms
6
Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasm Metastasis
4
Stomach Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Solid Tumors
2
Multiple Myeloma
2
Mouth Neoplasms
2
Lymphoma
2
Laryngeal Neoplasms
2
Hypopharyngeal Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Carcinoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Cancers
1
Skin Diseases
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Interventions
Oxaliplatin
46
Gemcitabine
45
Fluorouracil
40
Capecitabine
31
pembrolizumab
30
Leucovorin
29
Docetaxel
27
Cisplatin
25
Paclitaxel
23
Irinotecan
18
Carboplatin
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
17
Radiotherapy
16
Pemetrexed
15
Albumin-Bound Paclitaxel
15
Nivolumab
13
Ramucirumab
11
Cyclophosphamide
11
Drug Therapy
9
Trastuzumab
8
Erlotinib Hydrochloride
8
zolbetuximab
7
Taxes
7
Radiosurgery
7
trastuzumab deruxtecan
6
cemiplimab
6
Blood Specimen Collection
6
regorafenib
5
durvalumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
ipatasertib
×
Clear all
NCT04739202
2026-06-09
IMMUNOGAST
Hospices Civils de Lyon
Phase 2
Completed
54 enrolled